Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10188)
All Articles published online
|
Publishing Process of This Article
|
Jan 14, 2020 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lv XY, Ding HG, Zheng JF, Fan CL, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol 2020; 26(2): 199-218 [PMID: 31988585 DOI: 10.3748/wjg.v26.i2.199] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i2/199.htm |
| Number | Citing Articles |
| 1 |
Bradley Reuter, Jasmohan S. Bajaj. Microbiome. Clinics in Liver Disease 2020; 24(3): 493 doi: 10.1016/j.cld.2020.04.006
|
| 2 |
T. E. Polunina. Risk stratification in alcoholic cirrhosis of the liver: a case study. Meditsinskiy sovet = Medical Council 2023; (8): 126 doi: 10.21518/ms2023-129
|
| 3 |
Richard J Aspinall, Mark Hudson, Stephen D Ryder, Paul Richardson, Elizabeth Farrington, Mark Wright, Robert T Przemioslo, Francisco Perez, Melanie Kent, Roland Henrar, Joe Hickey, Debbie L Shawcross. Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II). Frontline Gastroenterology 2023; 14(3): 228 doi: 10.1136/flgastro-2022-102221
|
| 4 |
Francisco Idalsoaga, Camila Robles, Andrea Ortiz, Oscar Corsi, Eduardo Fuentes-López, Luis Antonio Díaz, Gustavo Ayares, Marco Arrese, Juan Pablo Arab. Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848241254267
|
| 5 |
Charles E. Gallaher, Debbie L. Shawcross. Management of Multidrug-Resistant Infections in Cirrhosis. Seminars in Liver Disease 2022; 42(02): 173 doi: 10.1055/a-1765-0056
|
| 6 |
Xiaoli Hua, Hao Feng. Changes in intestinal microbiota of HBV-associated liver cirrhosis with/without hepatic encephalopathy. Medicine 2022; 101(33): e29935 doi: 10.1097/MD.0000000000029935
|
| 7 |
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota. World Journal of Gastroenterology 2023; 29(27): 4236-4251 doi: 10.3748/wjg.v29.i27.4236
Abstract(624) |
Core Tip(554) |
Full Article(HTML)(3252)
|
Full Article with Cover (PDF)-2077K(107)
|
Full Article (Word)-351K(58)
|
Audio-395K(9)
|
Peer-Review Report-291K(62)
|
Answering Reviewers-97K(72)
|
Full Article (PDF)-967K(294)
|
Full Article (XML)-396K(77)
|
Times Cited (11)
|
Total Visits (7054)
|
Open
|
| 8 |
Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos de Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers, Pere Ginès. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021; 74(3): 1660 doi: 10.1002/hep.31708
|
| 9 |
Aleksander Krag, Jasmohan S. Bajaj. Portal Hypertension VII. 2022; : 311 doi: 10.1007/978-3-031-08552-9_26
|
| 10 |
Jasmohan S Bajaj, Amirhossein Shamsaddini, Chathur Acharya, Andrew Fagan, Masoumeh Sikaroodi, Edith Gavis, Sara McGeorge, Alexander Khoruts, Michael Fuchs, Richard K Sterling, Hannah Lee, Patrick M Gillevet. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. Gut Microbes 2021; 13(1) doi: 10.1080/19490976.2021.1993584
|
| 11 |
Aldo Torre, Jacqueline Córdova-Gallardo, Alberto C Frati Munari. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier. Therapeutics and Clinical Risk Management 2023; : 839 doi: 10.2147/TCRM.S425292
|
| 12 |
Ne’matjon Mamasoliev, Ibragim Askarov, Nasrulla Khakimov, Burkhonjon Usmonov, Oybek Umurzaqov, Bakhtiyor Nazarov, M.-T. Liong, I.V. Tkacheva. Liver cirrhosis in the elderly population: analysing prevalence and gender characteristics within the biotechnological framework. BIO Web of Conferences 2024; 84: 03004 doi: 10.1051/bioconf/20248403004
|
| 13 |
Rui-fang Zhu, Yu-lu Gao, Sue-Ho Robert, Jin-ping Gao, Shi-gui Yang, Chang-tai Zhu. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19). Journal of Translational Medicine 2020; 18(1) doi: 10.1186/s12967-020-02442-5
|
| 14 |
Maria J. Duarte, Phyllis C. Tien, Ma Somsouk, Jennifer C. Price. The human microbiome and gut–liver axis in people living with HIV. Current HIV/AIDS Reports 2023; 20(3): 170 doi: 10.1007/s11904-023-00657-x
|
| 15 |
Aanchal Bharti, Isar Sharma, Ritu Mahajan, Seema Langer, Nisha Kapoor. From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?). Indian Journal of Microbiology 2024; 64(3): 810 doi: 10.1007/s12088-024-01267-w
|
| 16 |
Igor G. Bakulin, Inna A. Oganezova, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva. Liver cirrosis and complication risk management. Terapevticheskii arkhiv 2021; 93(8): 963 doi: 10.26442/00403660.2021.08.200917
|
| 17 |
Li Wang, Zheng-Min Cao, Li-Li Zhang, Juan-mei Li, Wen-liang Lv. The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.923599
|
| 18 |
Maha Mohammad Elsabaawy, Medhat Assem, Hanaa Badran, Asmaa Mahmoud, Dalia Elsabaawy, Amr Ragab. Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis. European Journal of Gastroenterology & Hepatology 2024; 36(8): 1022 doi: 10.1097/MEG.0000000000002797
|
| 19 |
Paolo Caraceni, Juan G. Abraldes, Pere Ginès, Phil N. Newsome, Shiv K. Sarin. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. Journal of Hepatology 2021; 75: S118 doi: 10.1016/j.jhep.2021.01.024
|
| 20 |
MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan. Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure. Seminars in Liver Disease 2023; 43(04): 429 doi: 10.1055/s-0043-1776773
|
| 21 |
Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites. Medicina 2022; 58(9): 1276 doi: 10.3390/medicina58091276
|
| 22 |
Kensuke Kitsugi, Kazuhito Kawata, Hidenao Noritake, Takeshi Chida, Kazuyoshi Ohta, Jun Ito, Shingo Takatori, Maho Yamashita, Tomohiko Hanaoka, Masahiro Umemura, Moe Matsumoto, Takafumi Suda. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation. Journal of Clinical Medicine 2023; 12(6): 2210 doi: 10.3390/jcm12062210
|
| 23 |
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseases. Biomedicine & Pharmacotherapy 2024; 178: 117283 doi: 10.1016/j.biopha.2024.117283
|
| 24 |
Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross. Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transplantation 2022; 28(4): 700 doi: 10.1002/lt.26353
|
| 25 |
Xiao Yu, Ye Jin, Wangxiao Zhou, Tingting Xiao, Zhongwen Wu, Junwei Su, Hainv Gao, Ping Shen, Beiwen Zheng, Qixia Luo, Lanjuan Li, Yonghong Xiao. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Frontiers in Cellular and Infection Microbiology 2022; 11 doi: 10.3389/fcimb.2021.761192
|
| 26 |
皓月 田. The Application of Rifaximin in Patients with End Stage Liver Disease. Advances in Clinical Medicine 2024; 14(01): 466 doi: 10.12677/ACM.2024.141067
|
| 27 |
Mei‐Tong Nie, Pei‐Qin Wang, Pei‐Mei Shi, Xia‐Lu Hong, Xin Zhang, Baoyu Xiang, Menghui Zhang, Wei‐Fen Xie. Rifaximin treatment shapes a unique metagenome‐metabolism network in patients with decompensated cirrhosis. Journal of Gastroenterology and Hepatology 2024; 39(4): 762 doi: 10.1111/jgh.16484
|
| 28 |
Giacomo Zaccherini, Manuel Tufoni, Mauro Bernardi, Paolo Caraceni. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. Journal of Clinical Medicine 2021; 10(19): 4590 doi: 10.3390/jcm10194590
|
| 29 |
Fares E.M. Ali, Mustafa Ahmed Abdel-Reheim, Emad H.M. Hassanein, Mostafa K. Abd El-Aziz, Hanan S. Althagafy, Khalid S.A. Badran. Exploring the potential of drug repurposing for liver diseases: A comprehensive study. Life Sciences 2024; 347: 122642 doi: 10.1016/j.lfs.2024.122642
|
| 30 |
Simona Parisse, Quirino Lai, Francesca Martini, Alice Martini, Flaminia Ferri, Monica Mischitelli, Fabio Melandro, Gianluca Mennini, Massimo Rossi, Domenico Alvaro, Stefano Ginanni Corradini. Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy. Journal of Clinical Medicine 2023; 12(21): 6871 doi: 10.3390/jcm12216871
|